Research Analysts Offer Predictions for DFTX Q2 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for Definium Therapeutics in a note issued to investors on Wednesday, May 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.51) per share for the quarter, down from their previous estimate of ($0.46). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.10) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($1.22) EPS.

Several other research firms have also issued reports on DFTX. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of Definium Therapeutics in a research report on Thursday, April 23rd. Wolfe Research initiated coverage on shares of Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 price objective on the stock. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Finally, Jefferies Financial Group initiated coverage on Definium Therapeutics in a report on Thursday, January 29th. They set a “buy” rating and a $30.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $37.92.

Definium Therapeutics Price Performance

NASDAQ:DFTX opened at $21.35 on Friday. The stock has a market capitalization of $2.13 billion, a PE ratio of -8.57 and a beta of 2.37. Definium Therapeutics has a 1-year low of $6.28 and a 1-year high of $26.25. The firm has a fifty day simple moving average of $20.39 and a 200 day simple moving average of $16.36. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Palumbo Wealth Management LLC boosted its holdings in shares of Definium Therapeutics by 18.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after acquiring an additional 6,073 shares during the period. Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics during the fourth quarter worth approximately $117,000. Bay Rivers Group lifted its holdings in Definium Therapeutics by 14.3% during the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after purchasing an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Definium Therapeutics in the 3rd quarter valued at $107,000. Finally, Caxton Associates LLP bought a new stake in Definium Therapeutics in the 3rd quarter valued at $126,000. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.